No. 26 (2018), Resumos
No. 26 (2018)

Cost-effectiveness analysis of influenza A (H1N1) chemoprophylaxis in unified health system in Brazil

Resumos
Published 2019-02-12
Luisa Von Zuben Vecoso
Universidade Estadual de Campinas
Tais Freire Galvao
Universidade Estadual de Campinas
Marcus Silva
Universidade Federal do Amazonas
Everton Silva
Universidade de Brasília
Mariangela Resende
Universidade Estadual de Campinas
PDF

Keywords

Cost-effectiveness
Influenza
Brazil.

How to Cite

VECOSO, Luisa Von Zuben; GALVAO, Tais Freire; SILVA, Marcus; SILVA, Everton; RESENDE, Mariangela. Cost-effectiveness analysis of influenza A (H1N1) chemoprophylaxis in unified health system in Brazil. Revista dos Trabalhos de Iniciação Científica da UNICAMP, Campinas, SP, n. 26, 2019. DOI: 10.20396/revpibic262018926. Disponível em: https://econtents.sbu.unicamp.br/eventos/index.php/pibic/article/view/926. Acesso em: 22 apr. 2026.
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver

Download Citation

Endnote/Zotero/Mendeley (RIS) BibTeX

Abstract

BACKGROUND: Oseltamivir and zanamivir have indication for treating symptomatic flu and in prophylaxis in epidemics for groups with high risk of complications. METHODS: Effectiveness data was identified in literature review, and costs were obtained from official systems and micro-costing. RESULTS: We adopted a decision-tree model to assess the effectiveness of chemoprophylaxis in Brazilian Unified Health System (SUS) perspective with willingness to pay BRL 30,000.00/QALY. The incremental cost-effectiveness ratio for chemoprophylaxis compared to no prophylaxis was - 2,921.14/QALY. CONCLUSION: Chemoprophylaxis is cost-effective in Brazilian scenario.

PDF
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright (c) 2019 Luisa Von Zuben Vecoso, Tais Freire Galvao